Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Open access

Abstract

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this preclinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. Significance: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC. This article is highlighted in the In This Issue feature, p. 1079

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0116

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 301

Metadata

Authors
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C.
Affiliations
  • Yonsei University (KR)
  • Jeuk (South Korea) (KR)
  • 4Janssen Research and Development, Spring House, Pennsylvania.
Venue
Cancer Discovery
Published
2020-08-01
Volume
10
Issue
8
Pages
1194-1209
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3024670790
Cited by
297
References
47
Citations by year
2026: 32 · 2025: 60 · 2024: 45 · 2023: 52 · 2022: 49 · 2021: 47 · 2020: 11
FWCI
22.41
Type
journal article
Language
en
Licence
cc-by-nc-nd
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Funders
Ministry of Science, ICT and Future Planning (NRF-2016R1A2B3016282, 2018R1C1B6008916)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
amivantamab, EGFR-MET bispecific antibody, EGFR exon 20 insertion, non-small cell lung cancer, anticancer activity, EGFR tyrosine kinase inhibitors, immune checkpoint blockade, interferon-gamma, patient-derived organoids, xenograft models, cetuximab, poziotinib, Ba/F3 cells
MeSH terms
Antineoplastic Agents, Immunological, Animals, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Cell Line, Tumor, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0116
The paper
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C. (2020). Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.